OVID Valuation

Ovid Therapeutics Inc

Add to Watchlist

Advanced Chart

0.323

+0.008(+2.540%)

Overview
Forecast
Valuation

OVID Relative Valuation

OVID's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, OVID is overvalued; if below, it's undervalued.

Historical Valuation

Ovid Therapeutics Inc (OVID) is now in the Fair zone, suggesting that its current forward PS ratio of 114.03 is considered Fairly compared with the five-year average of 459.42. The fair price of Ovid Therapeutics Inc (OVID) is between 0.05 to 1.19 according to relative valuation methord.

Relative Value

Fair Zone

0.05-1.19

Current Price：0.32

Fair

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

0.34

P/B

Median3y

1.51

Median5y

2.48

-233.01

FCF Yield

Median3y

-52.22

Median5y

-25.12

Competitors Valuation Multiple

The average P/S ratio for OVID's competitors is 44.60, providing a benchmark for relative valuation. Ovid Therapeutics Inc Corp (OVID) exhibits a P/S ratio of 114.03, which is 155.70% above the industry average. Given its robust revenue growth of -46.31%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

OVID.O

Ovid Therapeutics Inc

114.03

Average P/S: 44.60

-46.31%